Alvotech , the biosimilars-focused sister company of Icelandic firm Alvogen, is continuing efforts to expand its biosimilars presence across the globe, signing an exclusive partnership with Cipla’s subsidiary in South Africa that will “ensure access to biosimilars” in the country.
Alvotech And Cipla Strike Biosimilars Alliance In South Africa
Deal Covers Five Undisclosed Biosimilars
Alvotech, fresh from a round of financing, has grand plans to market its biosimilar candidates across the globe. A new partnership just signed with South Africa-based Cipla Medpro will cover five candidates, including two in oncology.
More from Biosimilars
More from Products
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.